Alzamend Neuro (ALZN)Director bought ~$109K

~$109K

Approx. value · 108K sh @ $1.00

117K

Holds after · shares reported

Traded

Apr 14, 2026

Filed

Aug 31, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 6, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
2. Mar 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On March 20, 2026, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications staff (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 (the “ Form 10-Q ”), did not satisfy the continued listing…”

What came next

1. Aug 3, 2026Company filing · Form 8-K · Material agreement, Listing noticeReceived a notice from its stock exchange, and signed an important agreement (and 2 more items)“On July 20, 2026, the Company notified Nasdaq that it was not in compliance with the majority independent board standard under Nasdaq Listing Rule 5605(b)(1) which requires listed companies to have a majority of the board of directors be comprised of “Independent Directors” (as defined in Nasdaq Listing Rule 5605(a)(2)) (the “ Majority Independent Board Standard ”).”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alzamend Neuro

For Alzamend Neuro, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALZN page.

Other recent filings by Milton C Iii Ault, Director

• SEC Form 4 at Hyperscale Data (GPUS)Oct 1, 2026
• SEC Form 4 at Hyperscale Data (GPUS)Oct 1, 2026
• SEC Form 4 at Hyperscale Data (GPUS)Sep 28, 2026
• SEC Form 4 at Hyperscale Data (GPUS)Sep 28, 2026
• SEC Form 4 at Hyperscale Data (GPUS)Sep 28, 2026

The full history of Milton C Iii Ault, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Alzamend Neuro

• SEC Form 4Aug 31, 2026
• SEC Form 4Aug 31, 2026
• SEC Form 4Dec 30, 2025
• SEC Form 4Dec 23, 2025
• SEC Form 4Oct 24, 2025
• SEC Form 4Oct 10, 2025

Everything OQRO holds on this company is on its ALZN page.